• Pietro Bertini, Fabio Guarracino, Marco Falcone, Pasquale Nardelli, Giovanni Landoni, Matteo Nocci, and Gianluca Paternoster.
• Department of Anesthesia and Critical Care Medicine, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
• J. Cardiothorac. Vasc. Anesth. 2022 Aug 1; 36 (8 Pt A): 270027062700-2706.

ObjectiveTo analyze the survival rates of patients with COVID-19 supported with extracorporeal membrane oxygenation (ECMO) and compare the survival rates of patients with COVID-19 supported with ECMO to patients with influenza supported with ECMO.DesignA systematic review and meta-analysis to assess the impact of ECMO as supportive therapy of COVID-19.SettingThe authors performed a search through the Cochrane, EMBASE, and MEDLINE/PubMed databases from inception to February 19, 2021, for studies reporting hospitalized patients with COVID-19 managed with ECMO.ParticipantsA total of 134 studies were selected, including 6 eligible for the comparative meta-analysis of COVID-19 versus influenza.InterventionsThe authors pooled the risk ratio and random effects model.Measurements And Main ResultsThe primary endpoint was the overall mortality of patients with COVID-19 receiving ECMO. Of the total number of 58,472 patients with COVID-19 reported, ECMO was used in 4,044 patients. The analysis suggested an overall in-hospital mortality of 39% (95% CI 0.34-0.43). In the comparative analysis, patients with COVID-19 on ECMO had a higher risk ratio (RR) for mortality when compared to influenza patients on ECMO: 72/164 (44%) v 71/186 (38%) RR 1.34; 95% CI 1.05-1.71; p = 0.03.ConclusionsECMO could be beneficial in patients with COVID-19, according to the authors' meta-analysis. The reported mortality rate was 39%. This systematic analysis can provide clinical advice in the current era and ongoing pandemic.Copyright © 2021 Elsevier Inc. All rights reserved.

15 keywords...

hide…